Single-arm, prospective observational study
This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.
Study Type
OBSERVATIONAL
Enrollment
75
For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery
Hanover, Germany
RECRUITINGDonor-specific Antibodies Clearance
The DSA clearance is defined as absence of DSA in the Luminex test, which is performed every 6 months after treatment end.
Time frame: 6, 12, 18, 24 months
Graft survival
Graft survival is defined as freedom from mortality and re-transplantation
Time frame: 1, 3, 5 years
Incidence of acute cellular and humoral rejections and chronic lung allograft dysfunction (CLAD)
Time frame: 1, 3, 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.